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THE EFFECTS OF ELEVATED HEMOGLOBIN A1C ON COGNITIVE 
FUNCTION IN ELDERLY TYPE II DIABETICS IN THE LOOK AHEAD STUDY 
 
ANNE E. GOLDRING   
 
 
ABSTRACT 
 
Objective: Prolonged elevation of blood glucose levels in Type 2 Diabetes is related to a 
host of medical complications, most of which are mediated by micro and macro vascular 
damage. Importantly, diabetes is associated with accelerated cognitive decline and 
compromised brain health as the cerebral vasculature undergoes negative changes 
stemming from hyperglycemia. It is hypothesized that participants in the Look Ahead 
Brain study with higher HbA1c levels will exhibit worse performance on the cognitive 
measures, specifically on tasks assessing executive function.   
Methods: Data on participants from the Look Ahead study who also participated in the 
Look Ahead Brain ancillary study (n = 113) were analyzed. This included HbA1c levels 
at year 10 (the year that participants were administered the cognitive assessment), mean 
HbA1c, and change in HbA1c from baseline to year. In order to assess executive function 
the results on two cognitive tests, the Modified Stroop Color and Word Test and the Trail 
Making Test, were analyzed.  Then, relationships between HbA1c and performance on 
each of these cognitive tasks were analyzed using two approaches. First, the cohort was 
split into two group based on HbA1c (HbA1c ≤ 7% vs HbA1c > 7%). The latter of the 
two groups represented participants will poorer glycemic control.  Second, linear 
correlations were assessed using the full range of HbA1c values as a continuous variable. 
 vi 
Results: There were no significant differences between HbA1c groups and performance 
on either of the cognitive tests. Interestingly, although not statistically significant, those 
with higher HbA1c levels performed slightly better on cognitive tasks.  Correlation 
analyses revealed further trends in the direction opposite than expected, such that higher 
HbA1c levels were associated with better scores on both tests.  
Conclusion: The surprising results of this study are evidence of the fact that a great deal 
has yet to be learned about the effects of T2DM and cognitive decline. There are many 
potential future directions for the Look Ahead Brain data, and further analyses might 
provide clarifications to the results of this study.  
 vii 
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INTRODUCTION 
   
An Introduction to Diabetes Mellitus  
Diabetes mellitus (DM) affects 25.8 million people in the United States, equal to 
8.3% of the American population, and Type 2 Diabetes Mellitus (T2DM) accounts for 
90% to 95% of all diagnosed cases of diabetes (Prevention, 2011).  Figure 1 demonstrates 
that the prevalence of diabetes continues to rise (Figure 1). The occurrence of T2DM 
continues to rise because of the aging American population, along with the fact that a 
majority of Americans have adopted sedentary lifestyles resulting in obesity (Sullivan et 
al., 2005).   
 
 
Figure 1: Number of people (in millions) diagnosed with diabetes between 1981 and 
2011 in the Unites States. This figure demonstrates the increased incidence of DM in 
more recent years (Figure from Centers for Disease Control and Prevention, 2013). 
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DM is a metabolic disorder characterized by elevated blood glucose levels, 
referred to as hyperglycemia. A healthy individual has a tightly-regulated fasting blood 
glucose concentration between 70-100 mg/dl, whereas a type 2 diabetic has a fasting 
blood glucose concentration of 126 mg/dl or higher (American Diabetes Association, 
2013).  The hyperglycemia that occurs in type 2 diabetics is due to four main metabolic 
irregularities, which include obesity, abnormal insulin secretion and function, and 
increased basal levels of glucose production (Weyer et al., 1999).  Impairment of proper 
insulin function is the hallmark of T2DM (Abdul-Ghani et al., 2006).   
 
Pathogenesis of T2DM 
Insulin, the hormonal mediator necessary for cellular uptake of glucose, plays the 
important role of maintaining the body’s delicate balance between the fed and fasted 
states (Boron & Boulpaep, 2009).  There are four main organs involved in energy 
metabolism: the liver, adipose tissue, skeletal muscle, and the brain (Kahn, 1994).  
Energy to these tissues ultimately comes in the form of glucose, the body’s principle 
source of fuel (Abdul-Ghani et al., 2006).  In the two to four hours following a meal, also 
referred to as the absorptive state, the breakdown of carbohydrates into smaller sugars, 
such as glucose, leads to a spike in blood sugar levels (Harvey & Ferrier, 2011).   
Traveling in the blood, glucose makes its way to the pancreas where it prompts the 
glucose-sensitive beta cells to release insulin (Abdul-Ghani et al., 2006).  Working as an 
anabolic signal, insulin targets peripheral tissues to take up glucose (Harvey & Ferrier, 
2011). Insulin promotes glucose uptake in adipose tissue, the liver, and skeletal muscle 
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(entry into cells in the brain in not mediated) by activating insulin-sensitive glucose 
transporters that lie in the cellular membrane. The combination of signaling from insulin 
(hyperinsulinemia) plus the presence of glucose (hyperglycemia) serve to trigger glucose 
storage as glycogen in the tissues, as well as signal to the liver to stop glucose production 
(Abdul-Ghani et al., 2006).  The opposite is true in the fasted state, as the drop in blood 
glucose and reduced insulin secretion both promote glucose production.  Without the 
proper function of insulin these various processes are unable to adequately control blood 
sugar levels, as is the case in patients with T2DM. 
Type 2 diabetics suffer from two significant abnormalities pertaining to insulin 
(Figure 2).  First, the beta cells in the pancreas do not produce sufficient amounts of 
insulin in response to elevated blood glucose (Kahn, 1994).  As was previously described, 
the presence of glucose in the blood stream typically causes the pancreas to secrete 
insulin. However, in diabetics this is not the case, as the beta cells do not adequately 
respond to the surge in glucose. As a result, there is not enough insulin to sufficiently 
trigger glucose uptake in the various tissues throughout the body. Secondly, the 
hepatocytes, adipocytes, and skeletal muscle cells exhibit insulin-insensitivity (Kahn, 
1994).  Insulin resistance refers to the inability of these target tissues to properly respond 
to insulin (Kahn, 1994).  For unknown reasons the glucose transporters do not respond to 
insulin as they normally should, meaning that glucose cannot enter these cells and 
remains in the blood stream. Another consequence of insulin insensitivity is that the liver 
continues to make and release glucose. Not only are insulin levels insufficient to 
compensate for rises in blood glucose, but the insulin that is secreted cannot adequately 
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communicate with its target tissues. As a result, blood glucose levels remain elevated due 
to lack of proper glucose absorption and maintained glucose production. If diabetes goes 
untreated the hyperglycemia that persists poses a dangerous threat to every organ system.  
 
Figure 2: Causes of hyperglycemia in T2DM. There are two main contributing factors 
to the hyperglycemia associated with T2DM. First, there is insulin-resistance in 
peripheral tissues, so that these cells take up less glucose. Secondly, there is insufficient 
production and release of insulin from the beta cells of the pancreas (Figure from Harvey 
& Ferrier, 2011).  
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Obesity and Diabetes 
T2DM is a heterogeneous metabolic syndrome that results from a complex 
interplay between genetics and environment (Harvey & Ferrier, 2011).  Recent trends 
indicate that T2DM is reaching epidemic proportions predominately due to changes in 
environmental factors. More specifically, the simultaneous occurrence of the obesity 
epidemic alongside the rise in T2DM is no coincidence (Wild et al., 2004).  A body mass 
index (BMI) of 25 kg/m2 or higher classifies a person as overweight and a BMI of 30 
kg/m2is considered obese ("Overweight and obesity," 2012).  More than 1/3 of US adults 
are obese and 1 in 6 children are obese (Figure 3).  
 
 
Figure 3: Percentage of obese adults in the US between 2011-2012. 35.7% of 
American adults are obese (Figure from Ogden et al.,  2012). 
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These statistics are an unfortunate consequence of increasingly sedentary 
lifestyles and poor nutritional choices. These behaviors have evolved over the past few 
decades for a number of reasons. There have been significant changes in the way that 
people eat, which include increased portion sizes, instead of having nightly home-cooked 
meals people eat out at restaurants more often, fast food chains have become more 
prevalent, and sugary, processed food and beverages (which are higher in calories, fat and 
sugar) are readily available at reduced cost ("What causes overweight," 2012). People are 
also less physically active. This is in part due to the conveniences of technology; for 
example, jobs require more time in front of a computer or on the phone ("What causes 
overweight," 2012).  People also drive more as cities continue to increase in size, making 
walking or biking less feasible ("What causes overweight," 2012).  In addition, the 
childhood obesity epidemic contributes to the growing number of overweight adults. A 
reduction in physical activity and poor nutrition are the driving forces behind the 
childhood obesity epidemic, as children who receive regular physical education at school 
and regularly eat well-balanced meals prepared at home have a lower incidence of 
obesity (Veugelers & Fitzgerald, 2005).  All of these factors, along with many others, 
have contributed to the obesity epidemic and obesity poses a direct threat for the 
development of T2DM. 
The most common cause of insulin resistance is obesity, but that is not to say that 
obesity alone causes T2DM (Kahn, 1994).  While being over weight presents a direct risk 
for developing an insulin resistance, in order for an individual to become diabetic there 
must also be a defect with the beta cells of the pancreas (Harvey & Ferrier, 2011).  Most 
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non-diabetic obese individuals exhibited increased levels of insulin, hyperinsulinemia, to 
compensate for the insulin insensitivity of their cells. As a result, many obese people are 
able to control their blood glucose levels within the same range as a healthy person 
(Figure 4).  However, as time goes on increased demand on beta cells to produce more 
and more insulin can lead to their dysfunction (Weiss et al., 2005) (Figure 5).  Ultimately 
the beta cells cannot produce enough insulin to control the blood glucose, making the 
individual at increased risk for T2DM. This is in part what accounts for the increased 
diagnosis of T2DM with old age.  
 
 
Figure 4: Insulin and glucose levels in obese versus normal weight. As the diagram 
demonstrates, non-diabetic, obese individuals can initially control their blood glucose 
within a normal range by compensating via increased insulin production, a condition 
referred to as hyperinsulinemia (Figure from Harvey & Ferrier, 2011). 
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Figure 5: Progression from insulin resistance to T2DM. Obesity is the most 
significant cause of insulin resistance. However, in order for insulin insensitivity to 
become diabetes, the beta cells of the pancreas must become damaged, which can occur 
over time (Figure from Harvey & Ferrier, 2011).   
 
Comorbidities of Type II Diabetes 
The consequences of elevated blood sugar are dramatic and pervasive, resulting in 
both macro and micro-vascular damage. As a result, type II DM is associated with a host 
of other medical complications, which include, cardiovascular disease (CVD), stroke, 
dyslipidemia, kidney dysfunction, retinopathy and neuropathy (Harvey & Ferrier, 2011). 
Macrovascular changes account for increased incidence of CVD amongst diabetics. 
Hypertension is one of the major risk factors associated with diabetes, and is defined as a 
blood pressure greater than or equal to 140/80 mmHg. High blood pressure puts greater 
stress on the heart and causes hypertrophy of the heart muscle. Dyslipidemia is 
characterized as increased low-density lipoprotein cholesterol (LDL-C), decreased high-
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density lipoprotein cholesterol (HDL-C), and increased triglycerides (TG), all of which 
can lead to atherosclerosis (American Diabetes Association, 2013).  Atherosclerosis or 
thickening of arterial walls due to plaque accumulation has a variety of consequences. As 
the vessel wall stiffens and narrows the individual suffers from reduced blood flow to the 
heart, which puts a person at increased risk for a myocardial infarction (MI). In addition, 
if the plaque ruptures blood platelets are able to stick to the exposed plaque and clump 
together to form a clot. If a clot travels to the brain it can cause a stroke, which is the 
inability of oxygen-rich blood to perfuse brain tissue.  
Microvasculature changes, resulting from hyperglycemia, account for damage to 
the retina, kidneys, and nervous system. Retinopathy refers to degradation of the 
microvasculature of the retina, which in severe cases can lead to blindness. Nephropathy 
refers to the degradation of the nephron, or functional unit of the kidney. More 
specifically, hyperglycemia leads to break down of the glomerulus, the structure 
responsible for filtration of blood into urine. As the glomeruli loose their integrity normal 
filtration is impeded. As a result, proteins such as albumin inappropriately end up in the 
urine, a condition referred to as albuminuria. Ultimately, the progression of nephropathy 
can hinder the efficiency of the kidneys, which is indicated by a reduction in the 
glomerular filtration rate (GFR). Yet another unfortunate consequence of poor glycemic 
control is neuropathy, which affects both the autonomic and peripheral nervous systems. 
Prolonged hyperglycemia can result in peripheral nerve damage, causing reduced 
sensation in the extremities. Neuropathy usually presents as altered sensation in the hands 
and feet; diabetics report an uncomfortable tingling or prickling feeling, which can 
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progress into reduced or lost sensation all together. As a result, diabetics are at increased 
risk for undetected infection or injury to their feet, which when untreated can lead to the 
need for amputation. It is evident that diabetes has negative consequences on every organ 
system. While the severity of these conditions is variable between patients, the risk for 
such complications rises with poor glycemic control and duration of diabetes. 
 
Hyperglycemia and Glycosylation  
The exact mechanism to explain how hyperglycemia causes macro and 
microvascular damage remains unclear. The deleterious changes to the vasculature are 
initially mediated by the non-enzymatic condensation of glucose to cellular proteins, 
which occurs in cells where the entry of glucose does not depend on insulin (Harvey & 
Ferrier, 2011).  Glucose has the propensity to attach itself to proteins via a reaction that 
occurs in a two-step fashion. The first part of the reaction is reversible, whereas glucose 
irreversibly attaches to proteins during the second step. (Figure 6) The extent to which 
glycosylation occurs depends on the concentration of glucose in the blood (Harvey & 
Ferrier, 2011). Therefore, elevated blood sugar levels that accompany T2DM have the 
unfortunate consequence of producing glycated proteins. Unfortunately, the link between 
accumulation of glycated end products and vascular damage is not fully understood. 
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Figure 6: Temporary and Permanent Glycosylation of Proteins. Glucose readily 
attaches itself to proteins in a two-step process. The first step yields a temporary product 
(Schiff base), which is reversed if blood glucose levels reduce to normal. However if 
hyperglycemia persists the reaction proceeds through the second step, producing the 
irreversible glycosylation products (Figure from Bucala & Vlassara, 1995).  
 
An important example of this process is the formation of glycated hemoglobin 
(HbA1c). Importantly, red blood cells (RBC) are permeable to glucose. As a result, 
glucose can freely diffuse inside RBC and permanently attach itself to the hemoglobin 
protein. The lifespan of a RBC is about 120 days, therefore, HbA1c levels serve as an 
indication of blood glucose levels over a three to four month long period. A healthy 
individual has a HbA1c around 5%, whereas a diabetic is advised to maintain 7%. 
However, in populations with poorly controlled diabetes HbA1c reaches levels well 
above 11%. HbA1c measurements can serve as a powerful tool as it provides a look at a 
patient’s long-term diabetes control (Nathan et al., 1984).   
 
Treatment for Type II Diabetes 
 There is a great deal of evidence that suggests that T2DM can be controlled with 
lifestyle changes. Diabetics are encouraged to lose weight, exercise regularly, and 
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maintain a healthy diet. There are also a variety of medications that are effective for the 
treatment of diabetes if lifestyle modification is not enough. One such drug is metformin, 
which functions to reduce the insulin-resistance of peripheral tissues, as well as reduce 
the amount of glucose that the liver produces ("Type 2 diabetes,," 2013).  When 
metformin is not sufficient medications such as glipizide can be used to trigger insulin 
production and release from the pancreas. ("Type 2 diabetes,," 2013)  In addition, a 
physician might choose to prescribe a drug like acarbose, which will interfere with the 
breakdown of carbohydrates in the intestine ("Type 2 diabetes,," 2013).  Furthermore, if 
the disease worsens with time and the beta cells become compromised some diabetics 
require insulin injections. It is also highly recommended that patients monitor their blood 
sugar daily, as it is crucial that it stay within a healthy range. In addition to controlling a 
patient’s hyperglycemia (meaning a HbA1c less than 7%), the American Diabetes 
Association also recommends that diabetics keep their blood pressure (BP) below 140/80 
mmHg and low-density lipoproteion (LDL) cholesterol below 100 mg/dl (American 
Diabetes Association, 2013).  
 
The Look Ahead Study 
Despite the progress that has been made in treating T2DM, the medical and 
financial repercussions of this illness remain numerous. As a result, countless researchers 
around the world have dedicated their time and resources to learning more about T2DM. 
One such effort is the Look AHEAD study (LA), Action for Health in Diabetes, a 
multicenter randomized trial designed to assess the increased risk of CVD associated with 
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T2DM. Based on numerous short-term studies, it is accepted that weight loss and 
increased physical activity are beneficial in the reduction of CVD risk factors, such as BP 
and cholesterol ("Clinical guidelines on," 1998).  Relying on this knowledge LA set out 
with the primary objective to determine whether an intensive lifestyle intervention 
resulting in sustained weight loss would reduce CVD morbidity and mortality in older, 
overweight, type II diabetics.  The composite cardiovascular outcome included death 
from cardiovascular causes, nonfatal MI, nonfatal stroke, and hospitalization for angina 
(Wing et al., 2013).  
In 2001 LA enrolled 5000 individuals between the ages of 45-75, who had 
relatively well-controlled T2DM (HbA1c less than 11%) and were overweight or obese 
(BMI greater than 25 kg/m2) (Bertoni et al., 2008; Wing et al., 2013).  Participants were 
randomly divided into two groups, a control and intervention. The control group, 
Diabetes Support and Education (DSE), attended 3 sessions per year that provided basic 
education on nutrition, physical fitness, and proper diabetes care. The intervention group, 
or Intensive Lifestyle Intervention (ILI), attended weekly treatment sessions with a 
multidisciplinary team and motivational meetings during the first 6 months, with reduced 
frequency throughout the trial (Wing et al., 2013). Counseling for the ILI group was 
designed to help participants adopt a rigorous weight loss regimen via reduced caloric 
intake (1200 to 1600 kcal per day) and increased physical activity (175 minutes of 
moderate exercise per week) (Wadden, 2006).   
All participants had comprehensive annual health exams. Cardiovascular health 
was assessed with electrocardiograms, exercise stress tests (performed at years 1 and 4), 
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BP measurements, and blood draws (to measure HDL-C, LDL-C, and TG). Height, 
weight, BMI, and waist circumference were recorded. Glycemic control was assessed via 
measurements of blood glucose concentration and HbA1c. Renal function was evaluated 
with urine samples that provided levels of creatinine, albumin, and the GFR. Medication 
and doctor visits were recorded via interviewing. Exercise routines and eating habits were 
assessed with self-report questionnaires.  
As was hypothesized and expected, members of the intervention group achieved 
significant positive changes (Figure 7). The ILI group exhibited a 1-year mean 8.5% 
weight loss and 21% increase in physical fitness (Pi-Sunyer et al., 2007).  In addition, 
during the first year the ILI exhibited better glycemic control, indicated by the reduction 
in HbA1c (Figure 7). Furthermore, the ILI experienced improvements in all CVD risk 
factors including, BP, lipids, and HDL cholesterol, except for LDL cholesterol. However, 
these initially promising finding were not predictive of the results obtained during the 11-
year follow-up period. Despite a maintained weight loss of 6% in the ILI, compared to 
3.5% in the DSE, this did not translate into a sustained difference in incidence of CVD. 
There was no significant difference in the number of heart attacks, strokes, or deaths due 
to CVD between the two groups; the composite measures of CVD occurred in 403 ILI 
participants and 418 DSE members (Wing et al., 2013).  
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Figure 7: Differences in weight, physical activity, waist circumference, and HbA1c 
levels between DSE and ILI. Lifestyle modifications adopted in the ILI initially proved 
successful as the intervention group showed significant changes in comparison to the 
DSE. However, throughout the decade-long follow-up period differences between the 
two groups became less significant (Figure from Wing et al., 2013). 
 
As a result of the findings, which negated the primary hypothesis, the LA 
intervention was stopped. Despite the results, this is not to say that there was no 
difference in cardiovascular health between the ILI and DSE groups. As Dr. Nathan, a 
principal investigator and director of the Diabetes Center at Massachusetts General 
Hospital, pointed out, “the group assigned to diet and exercise ended up with about the 
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same levels of cholesterol, blood pressure and blood sugar as those in the control group, 
but the dieters used fewer medications.” While exercise and diet alone cannot completely 
eliminate the risk of CVD, they can take the place of medication in certain instances 
(Kolata, 2012).  This fact is significant as it implies that positive lifestyle choices have 
the ability to alter CVD risk factors enough to reduce medication use. In addition, 
members of the ILI sustained reduced HbA1c and as a result were less likely to be treated 
with insulin (Wing et al., 2013).  While these are not the substantial findings that LA 
researchers had hoped for, it at least indicates that efforts to achieve weight loss and 
physical fitness are not futile. Especially in these older individuals who suffer from the 
numerous consequences of chronic illness, any improvement in health and quality of life 
is beneficial.  
Despite terminating the intervention, LA has continued as an observational study, 
in which the ILI and DSE have been combined into a single cohort. LA provides a 
valuable opportunity to monitor aging in an over weight, diabetic population. The LA 
study refined its primary outcome to instead evaluate cognitive decline and physical 
function. The researchers hypothesize that there are potential long-term benefits of the 
10-year lifestyle intervention, which could account for differences in cognitive function 
between participants originally assigned to the ILI versus the DSE.   
 
The Look Ahead Brain Study 
 Prior to the changes to the LA study, the researchers were already interested in 
assessing cognitive function in LA participants because it is known that diabetics are at 
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increased risk for cognitive decline and more brain abnormalities (Biessels et al., 2008). 
Possible treatment strategies for preserving brain health in adults with T2DM have yet to 
be identified. While it has been shown that obesity is associated with reduced brain 
volume in healthy individuals, it is not clear whether weight loss in diabetics would 
convey a protective influence on cerebral health (Gunstad et al., 2008).  It has been 
proposed that behavioral interventions that encourage regular exercise and healthy 
nutrition resulting in weight loss (such as the one in Look Ahead) could have positive 
benefits on the brain (Araki & Ito, 2009).  As a result, the ancillary study Look Ahead 
Brain (LAB) was designed to assess the effect of weight loss on the brain health of LA 
participants by evaluating cognitive function and structural brain integrity. The 
expectation is that cognitive decline and brain atrophy will be worse in the DSE control 
group compared the ILI, as the intervention may have provided long-term benefits to 
brain health (Wing et al., unpublished). 
The LAB study is being conducted at 3 of the 16 LA sites: Providence, Pittsburgh, 
and Philadelphia. Participation in LAB is optional, but each site has been instructed to 
approach all of its participants in an attempt to recruit as many people as possible. LA 
subjects interested in participating in LAB sign a consent form. There are three separate 
parts of LAB; each component of LAB is offered independently of the others so that 
participants can pick and choose which tests they are willing to complete.  
The tasks associated with LAB include a paper-battery cognitive assessment, 
computer-based cognitive assessment referred to as the Toolbox, and magnetic resonance 
imaging (MRI) scan. It should be noted that prior to participation in the MRI portion of 
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LAB, participants are screened to determine whether or not they are eligible. Structural 
MRI (sMRI) is being used to evaluate hippocampal volume, total brain volume, and 
ischemic lesion volume. Hippocampal volume was selected as the primary outcome for 
the structural MRI for two main reasons; hippocampal atrophy is associated with obesity 
in type 2 diabetics, but importantly hippocampal volume is responsive to physical activity 
(Bruehl et al., 2009; Erickson et al., 2009).  In addition, reductions in hippocampal 
volume are related to cognitive dysfunction (Rasgon et al., 2009).  Functional MRI 
(fMRI) is used to assess various mechanisms through which the intervention might have 
affected brain function. The fMRI scans are addressing functional activation, brain 
networking, and cerebral blood flow. During the fMRI participants are asked to play a 
memory game, referred to as the N-back, which presents the subject with a continuous 
stream of letters, appearing one at a time, on the computer screen. Subjects play two 
alternating versions of the N-back game, the 1-back and the 2-back. During the 1-back 
participants are asked to indicate whether the letter they see on the screen is the same as 
the letter they saw one trial previously. During the 2-back, a slightly more challenging 
task, participants have to keep track of more letters and indicate whether the letter they 
see on the screen is the same as the letter they saw two trials previously. Measurements 
of functional activation, specifically in relation to working memory, provide an 
assessment of cognition involving the hippocampus. It has been hypothesized that the 
ILI, which provided subjects with better glycemic control, weight loss, and physical 
fitness, will be associated with greater hippocampal volume and cerebral blood flow 
(Wing et al., unpublished).  The paper-based battery and toolbox consist of a variety of 
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tasks that assess vocabulary, memory, reaction time, attentiveness, executive function, 
visuomotor skills and cognition. Collection and analysis of LAB data is ongoing.  
 
Effects of T2DM on Cognitive Change 
Impaired glucose tolerance, hyperglycemia, insulin resistance and 
hyperinsulinemia all contribute to cerebral dysfunction (Araki & Ito, 2009; Messier & 
Teutenberg, 2005). Cognitive decline in type 2 diabetics is associated with small vessel 
disease in the brain (Umegaki et al., 2012).  The vascular damage in the brain, which in 
turn leads to cognitive decline, is most likely mediated by the impairments related to 
insulin function and glucose tolerance. Multiple studies have demonstrated the 
deleterious effect of hyperglycemia on cognition. Elevated blood sugar can have toxic 
effects on the brain as glycation interferes with important proteins (Spauwen et al., 2013).  
This is supported by the findings from the Action to Control Cardiovascular Risk in 
Diabetes-Memory in Diabetes (ACCORD-MIND) study, which observed that higher 
levels of HbA1c were associated with poorer performance on a wide range of cognitive 
tasks (Cukierman-yaffe et al., 2009).  Umegaki et al found that while the effect of 
increased HbA1c measured at baseline on cognitive impairment was not significant, the 
level of HbA1c measured over a prolonged period of time was associated with cognitive 
impairment (Umegaki et al., 2012). It therefore stands to reason that diabetics with 
prolonged elevation of blood glucose levels are at increased risk for cognitive decline, in 
comparison to other diabetics with well-control blood sugar.  
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Interestingly, certain types of cognition seem to be affected by T2DM more than 
others. Executive function and information processing speed are more significantly 
compromised in type 2 diabetics than memory or language abilities (van den Berg et al., 
2009). The results of the Maastricht Aging Study support this finding, as they observed 
cerebral small vessel damage caused by diabetes to be strongly associated with reduced 
performance in information-processing speed and executive function (Figure 8) 
(Spauwen et al., 2013).  Furthermore, the Takahata study also observed performance on 
tasks that assess executive function was associated with HbA1c level (Takahashi et al., 
2011).  The results of the Takahata study confirmed that impaired glucose metabolism 
and the resulting hyperglycemia, independent of typical vascular risk factors and brain 
lesions that occur with aging, are associated with reduction in executive function amongst 
the elderly (Takahashi et al., 2011). 
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Figure 8: Effects of T2DM on task assessing executive function in the Maastricht 
Aging Study. Dark circles indicate participants without baseline diabetes. White circles 
indicate participants with baseline diabetes. Cognitive tests addressed information 
processing speed, immediate and delayed word recall (higher score indicates better 
performance), as well as concept shifting (lower score indicates better performance). It is 
evidence from the results of the Maastricht Aging Study that longer duration of diabetes 
is associated with reductions in information processing speed, compared to individuals 
without diabetes (Figure from Spauwen et al., 2013). 
 
 It is evident that the hyperglycemia associated with T2DM poses a serious threat 
to every organ system in the body. Perhaps most worrisome are the potential detriments 
to brain health. A great deal remains unclear about how T2DM is responsible for 
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cognitive decline, as many of the mechanisms have yet to be elucidated. There is a need 
for additional studies evaluating the effects of elevated blood sugar on cognitive function 
in type 2 diabetics, as the relationship between the two has been established but not well 
defined. More specifically, there is a need to more clearly identify if certain cognitive 
abilities are affected by diabetes more than others. This study aims to address this issue 
by using data on glycemic control from the LA study and assessment of cognitive 
function from LAB. By correlating HbA1c, a measure of hyperglycemia, with 
performance on certain cognitive tasks designed to assess executive function, we hope to 
show that elevated blood glucose has a negative impact on this specific type of cognitive 
performance.   
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Specific Aims 
The objective of the current study is to look at the relationship between HbA1c 
levels and executive function abilities, in order to determine whether elevated blood 
sugar has a deleterious effect on cognitive performance. Specifically: 
 
1. Data regarding cognitive performance will be collected on a cohort of 
participants in the LAB study. Candidates who have completed the paper-
battery cognitive assessment will be selected for analysis. 
2. Pperformance on two cognitive tasks that test executive function abilities, 
specifically, the Modified Stroop Color and Word Test (MSCWT) and the 
Trail Making Test-Part B (TMT-B) will be evaluated.  
3. Data from the LA study regarding HbA1c will be assessed, including the 
level measured at the time of the cognitive exam, the mean HbA1c and 
change in HbA1c over the10 year period in the LA trial.   
4. Potential for statistically significant associations between HbA1c levels 
and participants’ scores on the MSCWT and TMT-B will be determined.  
 
It is anticipated that this study will demonstrate a correlation between HbA1c and 
cognitive performance. More specifically, participants with higher mean HbA1c, which is 
indicative of longer-term poor glycemic control, are expected to have worse cognitive 
performance. It is hoped that this study provides evidence for the deleterious effects of 
hyperglycemia on cognition in type 2 diabetics.  
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METHODS 
 
Sample 
 This study is an analysis of existing clinical data on 113 participants from the LA 
study at the Providence, Rhode Island site, who also participated in the LAB ancillary 
study prior to September 1, 2013. There were 68 female and 45 male participants. The 
mean age of participants is 69.8 years. The mean BMI at year 10 was 33.7 kg/m2. All 
participants provided informed consent for the Look Ahead Study and the Look Ahead 
Brain Ancillary Study in accordance with the Miriam Hospital Internal Review Board.  
  
Procedures 
 HbA1c 
HbA1c levels were used to evaluate participants’ blood sugar control. HbA1c was 
attained from fasting blood draws taken by the study phlebotomist during annual visits. 
Blood draws were taken at baseline, years 1, 2, 3, 4, 6, 8 and 10.  
 
Cognitive Task, The Stroop 
In order to assess executive function, performance on the MSCWT was analyzed. 
The test consists of three separately administered cards (a word card, a color card, and a 
word-color card); the participant is asked to read each of the three cards as quickly as 
possible. Subtest 3 (the word-color card) of the MSCWT assesses peoples’ ability to 
respond to conflicting stimuli, requiring they respond to one stimulus (color) while 
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suppressing a reaction to the other, more prepotent, competing stimulus (word) (Stroop, 
1935).  The MSCWT measures processing speed and inhibition, both forms of executive 
function.  
The MSCWT is one of the various tasks administered during the paper-battery 
cognitive assessment, as a part of the LAB study which participants completed during 
either year 10 or 11 of the LA study. The cognitive assessment was administered by one 
of the research assistants in a quiet room without any distractions. The examiner timed 
the participant while he or she completed each task.  
The MSCWT consists of a series of three visual tests. During the first subtest, the 
participant is presented with a sheet that contains 40 word items denoting colors (red, 
blue, green or yellow) written in black ink. The participant is asked to read the names of 
the colors as quickly as possible without making mistakes. The second subtest contains 
40 colored bars. The examiner asks the participant to name the colors presented on the 
sheet. Finally, the Stroop subtest three contains 40 word items denoting the name of a 
color, but each word is printed in a different color of ink. For example, the word “green” 
is written in blue ink. The participant is asked to name the color of the ink, not to read the 
word for each item. A maximum time of 120 seconds is allotted for the first two tests and 
180 seconds is the limit for the third. For each subtest the time (in seconds) to recite all 
40 items is recorded, along with the number of errors the participant made. A 
participants’ score on the MSCWT was determined based on total time in seconds to 
complete a subtest plus the number of errors. A higher score is considered worse, as it 
implies that it took a longer time to complete the test and/or more errors were made. 
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Cognitive Task, Trail Making 
The second test of executive function that was analyzed was the TMT-B. The 
TMT-B was administered under the same conditions as the MSCWT. In the TMT-B 
participants are presented with 25 circles, which either contain a number (1-13) or a letter 
(A-L), dispersed non-sequentially across a sheet of paper. The respondent has to connect 
the circles in ascending numerical and alphabetical order, alternating between numbers 
and letters. The time (in seconds) to complete the task is the score. If an error is made it is 
immediately corrected by the examiner and accounted for in the score as it requires 
additional time to complete the task (REITAN, 1958).  The TMT-B requires the 
participant to shift between the alphabetical series and numerical series, which are sets of 
information that are typically considered separately. The TMT-B is the most widely used 
assessment for executive function. It should be noted that there is also a TMT-part A, 
which assesses concentration and memory. TMT-A consists of 25 numbered circles 
dispersed on a sheet of paper; the respondent is asked to connect the circles in numerical 
order. While we did not analyze the TMT-A data individually, we did incorporate the 
score on part A in a comparison to part B for the data analysis as TMT-A may be thought 
of as a control for psychomotor speed and general ability to connect numbers in 
sequence. 
 
Statistical Analysis 
In order to investigate the relationship between HbA1c and cognitive performance 
on tasks assessing executive function, several statistical tests were conducted using SPSS 
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software. Using the ADA recommendation to define optimal glycemic control as HbA1c 
< 7%, the cohort was split into two groups: participants with HbA1c ≤ to 7% and those > 
7% (American Diabetes Association, 2013).  Participants with HbA1c > 7% were 
considered as having suboptimal glycemic control. As we were most interested in 
assessing the effect of long-term blood glucose elevation on cognitive performance, 
analysis was focused on mean HbA1c levels in relation to score on the cognitive tasks.  
After analyzing the data in two groups, the data were then analyzed linearly. 
Since HbA1c levels are continuous in nature, with measurements for mean HbA1c in the 
current sample ranging from 5.19% to 9.01%, potential correlations between HbA1c 
levels were explored using the full range of these continuous data. Three different 
measurements of HbA1c were used.. First, the HbA1c level measured at the year of the 
cognitive assessment was considered. The mean HbA1c across the 10-year period was 
used as was the change in HbA1c calculated by subtracting the value at baseline from the 
value at year 10.  
Analysis of performance on the MSCWT was based on the score, which was 
generated from the difference in scores on subtest 3 and 2. In analyzing the data on TMT-
B two separate measures, the score on TMT-B and the difference between the score on 
TMT-B and TMT-A were considered. Given that increased age is thought to be 
associated with poorer cognitive performance (confirmed within this sample, MSCWT 
Pearson R = 0.318, p = 0.001, TMT-B Pearson R = 0.427, p < 0.001) and higher BMI 
may be additionally related to poorer cognitive performance, both age and BMI were 
covaried in these analyses (Chelune et al., 1986; Elias et al., 2003; Gunstad et al., 2007). 
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RESULTS 
 
HbA1c Values 
The mean HbA1c of the cohort over the 10-year trial was 7.05%, ranging from 
5.19% to 9.01%. The average HbA1c at year 10 (the year of the cognitive exam) was 
7.18% and the range was from 5.2% to 11.5%. The mean change in HbA1c from baseline 
to year 10 was -.22% and ranged from -8.4 to 4.8%.  Thus on average there was a slight 
decrease in HbA1c levels from baseline to year 10. The cohort was split into two groups 
based on mean HbA1c level, n = 60 for HbA1c ≤ 7 and n = 52 with HbA1c > 7.  
 
Cognitive Measures 
The mean score on the MSCWT (score [time to complete + number of errors] on 
Stroop 3 minus score on Stroop 2) was 31.25, ranging from -21 to 151. The mean score 
on TMT-B (time to complete trails B) was 107.91 seconds and ranged from 37 to 300 
seconds. The mean difference between TMT-B and TMT-A (the trails difference score) 
was 74.50 seconds and the range was from 11 to 269 seconds. A strong positive 
correlation was found between performance on the MSCWT compared to performance 
on TMT-B (Pearson R = 0.561, p < 0.001), as would be expected because both tests 
assess facets of executive function.  
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HbA1c & MSCWT 
Group differences  
The mean score on the MSCWT amongst participants in the group with HbA1c 
values ≤ 7% was 32.92 ± 2.72 (mean adjusted for age and BMI ± standard error) and the 
mean for the group with HbA1c > 7% was 29.02 ± 2.99 (Figure 8). It was observed that 
participants in the group with lower HbA1c had a higher average score on the Stroop, 
which is indicative of worse performance, however these differences were not significant 
[F(2,106)=0.896, p = 0.346].  
 
Correlations  
When the data were analyzed linearly, there were no significant correlations 
between either the mean HbA1c, year 10 HbA1c, or change in HbA1c and performance 
on the MSCWT (Table 1). We did observe a trend as mean HbA1c increased 
performance on the MSCWT improved (R = -0.157, p = 0.099), which was contrary to 
the original hypothesis. 
 
HbA1c & Trails 
Group differences 
 When analyzing data on the TMT-B, it was found that the mean score for 
participants with HbA1c ≤ 7% was 110.45 ± 8.56 and 102.02 ± 9.43 in the group with 
HbA1c > 7% (Figure 9). Although the directionality of this finding was also the opposite 
of what was expected , as participants with lower HbA1c levels performed more poorly, 
 30 
the differences were not significant [F(2,106)=0.423, p = 0.517].  The means from trails 
difference for the group with HbA1c ≤ 7% and HbA1c > 7% were 75.65 ± 7.74 and 70.24 
± 8.52 respectively and again, these differences were not significant [F(2,106)=0.213, p = 
0.646] (Figure 10). 
 
Correlations 
There were no significant findings other than a negative correlation between the 
trails difference and change in HbA1c (R = -0.193, p = .040) (Table 1). Trails difference 
is the score on TMT-B minus the score on TMT-A, where each score is simply the time 
(in second) to complete the task. Trails difference is a more accurate measurement of 
reaction time because it corrects for general ability to connect the dots in order. 
Therefore, a smaller trails difference is indicative of faster reaction time and better 
performance. Change in HbA1c is a measure of the difference in HbA1c level at year 10 
compared to baseline. A negative change represents an improved HbA1c. Whereas a 
positive change in HbA1c indicates that by year 10 HbA1c was greater than it was at 
baseline and therefore worse. The negative relationship that we observed between trails 
difference and change in HbA1c means that improved HbA1c was associated with worse 
performance on trails.  
 
 
 
 
 31 
Figures 
 
Figure 9: Comparison of performance on MSCWT between group with a mean 
HbA1c ≤ 7% versus HbA1c > 7%. No significant differences in MSCWT score and 
HbA1c group were observed (F<1). 
 
 
Figure 10: Comparison of performance on TMT-B between group with a mean 
HbA1c ≤ 7% versus HbA1c > 7%. No significant differences in TMT-B and HbA1c 
group were observed (F<1). 
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Figure 11: Comparison of trails difference score between group with a mean HbA1c 
≤ 7% versus HbA1c > 7%. No significant differences in Trails Difference score and 
HbA1c group were observed (F<1). 
 
Table 1: Correlation between HbA1c measures and performance on cognitive tests. 
The only significant correlation that we observed was between change in HbA1c and 
trails difference. *Correlations significant at the 0.05 level (2-tailed).  
 
 MSCWT TMT-B Trails Difference 
Year 10 HbA1c  
 
Pearson Correlation 
 
Significance  
(2-tailed) 
 
 
R = -0.035 
 
p = 0.717 
 
 
R = -0.070 
 
p = 0.473 
 
 
R = -0.082 
 
p = 0.395 
Mean HbA1c  
 
Pearson Correlation 
 
Significance  
(2-tailed) 
 
 
R = -0.157 
 
p = 0.099 
 
 
R = -0.144 
 
p = 0.129 
 
 
R = -0.128 
 
p = 0.175 
Change in HbA1c  
 
Pearson Correlation 
 
Significance  
(2-tailed) 
 
 
R = 0.097 
 
p = 0.310 
 
 
R = -0.153 
 
p = 0.106 
 
 
R = -0.193* 
 
p = 0.040 
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DISCUSSION 
 
Key Findings  
This study contributes to the existing research on cognitive decline associations 
with T2DM, in an attempt to elucidate the relationship between hyperglycemia and 
cognitive performance. As hyperglycemia is known to have adverse health consequences, 
particularly on the integrity of vasculature throughout the body, we hoped to study its 
effect on brain health and subsequent cognitive function. More specifically, we wanted to 
determine if prolonged elevated HbA1c was associated with a reduction in executive 
function. However, when examining those who had mean HbA1c within a recommended 
range (≤ 7%) compared to those with HbA1c outside this range (>7%), there were no 
significant differences in performance on cognitive tasks.  Although the differences were 
not statistically significant, the findings were surprisingly in the opposite direction from 
the original hypothesis.  That is, a worse performance in the group with mean HbA1c ≤ 
7% was observed. The correlation data also suggest a trend in the opposite direction than 
expected, but again, there was no significant relationship between the mean HbA1c level 
(measure over the 10-year trial in the LA study) or HbA1c measured at year 10 (the year 
of the cognitive exam) and performance on the TMT-B or MSCWT. These results were 
contrary to the original hypothesis, but can potentially be explained by limitations of the 
study.  
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Age & BMI 
  We controlled for the covariates age and BMI. Age is strongly correlated with 
performance on cognitive tests. As expected, a strong negative correlation was observed 
between age and performance on both the TMT-B and MSCWT (MSCWT Pearson R = 
0.318, p = 0.001, TMT-B Pearson R = 0.427, p < 0.001). Thus as the age of participants 
increased, so did the time required to complete both of the tests. In addition, BMI is 
typically associated with reduced performance on cognitive tests. However, the opposite 
was found to be true; BMI was negatively correlated with time to complete TMT-B 
(Pearson R = -0.236, p = .013) suggesting that higher BMIs were associated with better 
performance (i.e., reduced time to complete TMT-B). It is possible that this unexpected 
relationship is due to the fact that BMI and age are negatively correlated (Pearson R = -
0.339, p < 0.001). As people reach advanced ages and their health deteriorates, weight 
loss is a common side effect. Given these relationships, it is possible that the unexpected 
negative association between BMI and score could be explained because the more elderly 
participants who performed more poorly also had lower BMIs.   
 
Limitations 
It was surprising to observe a trend between higher HbA1c levels and worse 
cognitive performance, but this could be explained by certain limitations of the study. A 
potential limitation is that we did not account for medication use, specifically insulin. 
This might have explained why a negative correlation between age and HbA1c was 
observed. The fact that older participants had lower levels of HbA1c is initially 
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perplexing because a longer duration of diabetes is typically associated with worsening of 
the disease. However, this relationship could potentially be explained by the fact that 
older participants, who have had diabetes for a longer duration, typically end up on more 
medications, as well as insulin to control their HbA1c. This is supported by findings from 
an early analysis of LA data, which observed that older participants were more likely to 
meet HbA1c goals (Bertoni et al., 2008).  Insulin use amongst older participants might 
account for lower HbA1c and in turn explain why lower HbA1c levels were associated 
with worse performance. We could have also controlled for duration of diabetes because 
duration of diabetes is often associated with reduced cognitive function (Spauwen et al., 
2013).  
Another potential limitation of the study is that the population in the LA study, 
and therefore LAB, is a group of relatively well-controlled diabetics. In recruiting 
participants for the study the researchers set strict selection criteria in terms of glycemic 
control and only accepted individuals with a HbA1c ≤ 11%. The mean HbA1c of 
participants in this study was 7.05%, with a range of mean HbA1c was 5.19% to 9.01%, 
which is indicative of a population of relatively healthy diabetics. As a result, it is 
possible that participants in this cohort do not have hyperglycemia that is severe enough 
to impact cognitive impairment detectable with the paper-based cognitive assessment. 
Another possible interpretation is that the damage to their cerebral health, resulting from 
hyperglycemia, has not yet occurred perhaps because their diabetes is relatively well-
controlled.  Put simply, although LAB participants have potentially higher HbA1c levels 
than a healthy non-diabetic population, their HbA1c levels are likely considerably lower 
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than those of a broader range of diabetic individuals.  It is possible that the relationship 
between HbA1c and cognitive function is evident only in the highest ranges of HbA1c 
and future studies should explore this.  
Another limitation of this study and one of the significant criticisms of LAB is 
that there was not a cognitive assessment at baseline. Conducting the same cognitive 
measures pre-intervention would have allowed for proper comparisons over time. It 
would be useful to make within-subject comparisons to examine how cognitive 
performance changed over time. While it is to be expected that performance would 
decline with time due to the effects of natural aging, we could also account for any effect 
of prolonged elevation of HbA1c.   
   
Future Directions 
There are a variety of potential directions for the LAB data based on the 
implications of this study. In order to assess which regions of the brain have been 
affected by damage from diabetes in the LAB participants the researchers will rely on the 
MRI data. It would be interesting to see if participants who have compromised 
performance on certain cognitive tasks, particularly those testing executive function, also 
exhibit degeneration in brain regions thought to be involved in such processes. In 
addition, as other studies have shown that hyperglycemia is associated with reductions in 
information processing speed and executive function, we could assess whether the 
regions of the brain recruited during these tasks show evidence of degeneration due to 
T2DM in the LAB participants.  
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Another potential direction for LAB would be to complete another cognitive 
assessment in 5 years. This would allow for a comparison between the effects of T2DM, 
particularly HbA1c and the duration of diabetes, on cognition after 10 years in the study 
versus 15. Especially since so many of the participants have relatively well-controlled 
diabetes it would useful to see whether or not the consequences of their disease become 
apparent after 15 years, as opposed to 10. This could potentially provide researchers and 
physicians with the ability to estimate the time for the onset of cognitive decline in 
diabetics if they control their blood sugar within a certain (relatively healthy) range for 
over a decade.  
It would also be useful to compare the LAB participants to an age-matched non-
diabetic population. While there might not be detectable differences of the effect of 
hyperglycemia on cognition between LA participants (since the range of HbA1c levels 
was relatively small), their performance might be worse compared to non-diabetics. This 
would serve as evidence that elevated HbA1c has had adverse effects on the LAB 
population. Such findings were observed by the Takahata study, in which subjects with 
diabetes exhibited worse performance on tests evaluating executive function than non-
diabetics (Takahashi et al., 2011). 
Another potentially interesting direction for this data is the comparison of the ILI 
and DSE groups. It would be useful to determine whether or not there are differences 
pertaining to executive function between the two intervention groups. As the difference 
in HbA1c levels in ILI vs. DSE by the end of the 10-year trial was not substantial, if there 
are differences in cognition perhaps they are do to some other measure.  
 38 
Conclusions 
This study demonstrates the need for further research on hyperglycemia and 
cognitive function. The results indicate that the relationship between insulin resistance 
and hyperglycemia with cognitive decline is a potentially complex one. The LA study 
and LAB data provide a unique opportunity to study an aging diabetic population. While 
no one doubts the detrimental effects of T2DM, a great deal remains unknown about this 
increasingly prevalent chronic illness and future research is necessary to better 
characterize the pathogenesis of this disease.  
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